26 completed, 16 recruiting, 9 unknown, 8 terminated. 23 Phase 2, 18 Phase 3, 7 Phase 1, 6 Not applicable, 6 Phase 4.
Follow Primary Biliary Cholangitis: new trials by email Literature Review of Primary Biliary Cholangitis trials Research Report on Primary Biliary Cholangitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease | Phase 2 | Not yet recruiting | Mayo Clinic | 15 | 2026-11-01 | 2026-09-28 |
| Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis Seladelpar, PTM Seladelpar, Cilofexor Dose B - Primary Biliary Cholangitis | Phase 2 | Recruiting | Gilead Sciences | 132 | 2026-10-01 | 2026-10-27 |
| Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis Standard background therapy, Placebo, hUC-MSC Dose Level 1 - Primary Biliary Cholangitis | Phase 1 / Phase 2 | Not yet recruiting | Beijing 302 Hospital | 68 | 2026-08-31 | 2026-08-31 |
| Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy Saroglitazar Magnesium 1 mg, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Zydus Therapeutics Inc. | 90 | 2026-08-11 | 2026-09-15 |
| LEOPARD Prospective Validation Cohort 1 Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking - Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 630 | 2026-07-07 | 2026-07-29 | |
| The Value of Spleen Stiffness Measurement in Patients With PBC Spleen stiffness measurement - Primary Biliary Cholangitis, Spleen Stiffness | Not applicable | Not yet recruiting | Universitair Ziekenhuis Brussel | 125 | 2026-07-01 | 2026-05-01 |
| TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis Nalmefene, Placebo - Pruritus, Primary Biliary Cholangitis | Phase 2 | Not yet recruiting | Tharimmune Inc | 40 | 2026-06-01 | 2025-09-09 |
| Patients With Primary Biliary Cholangitis(PBC) Primary Biliary Cholangitis, Liver Fibrosis | Active not recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 30 | 2026-05-18 | 2026-06-05 | |
| Patients With Primary Biliary Cholangitis Reflex AMA and ANA testing - Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer | Not applicable | Active not recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2000 | 2026-04-23 | 2026-05-07 |
| Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes Saroglitazar magnesium 1 mg, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Zydus Therapeutics Inc. | 386 | 2026-03-24 | 2026-08-04 |
| Austrian PBC Registry Primary Biliary Cholangitis, Liver Cirrhosis | Recruiting | Medical University of Vienna | 500 | 2026-03-18 | 2026-05-20 | |
| Biochemical Response and Clinical Outcomes in Patients With PBC Only observation - Primary Biliary Cholangitis (PBC), Primary Biliary Cholangitis | Recruiting | RenJi Hospital | 3000 | 2026-02-01 | 2026-03-04 | |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA 2mg CS0159, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Cascade Pharmaceuticals, Inc | 135 | 2025-12-01 | 2026-07-08 |
| Monitoring the Response of Combination Ursodiol and Seladelpar Treatment Blood Draws - Primary Biliary Cholangitis | Not yet recruiting | Methodist Health System | 100 | 2025-08-01 | 2025-08-14 | |
| A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) Primary Biliary Cholangitis | Completed | Ipsen | 30 | 2025-07-16 | 2026-04-30 | |
| A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury CS0159 - Primary Biliary Cholangitis | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 24 | 2025-03-13 | 2025-07-11 |
| LEOPARD Training and Validation Data Collection Study Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 4500 | 2025-02-04 | 2026-07-29 | |
| A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) Elafibranor - Primary Biliary Cholangitis | Phase 3 | Active not recruiting | Ipsen | 18 | 2025-01-16 | 2026-10-23 |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment Primary Biliary Cholangitis | Active not recruiting | Ipsen | 424 | 2024-10-14 | 2026-10-23 | |
| A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. K-808 - Primary Biliary Cholangitis, Compensated Cirrhosis | Phase 1 | Completed | Kowa Research Institute, Inc. | 17 | 2024-10-01 | 2025-05-23 |
Showing 20 of 72. Sign in to see all of them.
Liver Cirrhosis, Biliary (72) · Cholangitis, Sclerosing (4) · Cholangitis (3) · Cholestasis (3) · Digestive System Diseases (3) · Liver Cirrhosis (3) · Pruritus (3) · Biliary Tract Diseases (2) · Fibrosis (2) · Hepatitis, Autoimmune (2) · Anxiety Disorders (1) · Arthritis, Rheumatoid (1) · Bile Duct Diseases (1) · Carcinoma, Hepatocellular (1) · Cardiovascular Abnormalities (1)
Cholestasis, Intrahepatic (72) · Liver Diseases (72) · Pathologic Processes (72) · Pathological Conditions, Signs and Symptoms (72) · Bile Duct Diseases (71) · Biliary Tract Diseases (70) · Fibrosis (70) · Cholestasis (69) · Digestive System Diseases (69) · Liver Cirrhosis (69) · Signs and Symptoms (5) · Cholangitis (4) · Skin Diseases (4) · Skin Manifestations (4) · Skin and Connective Tissue Diseases (4)
seladelpar (6) · Ursodeoxycholic Acid (4) · obeticholic acid (4) · saroglitazar (4) · Bezafibrate (3) · Fenofibrate (3) · (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (2) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (2) · Blood Specimen Collection (1) · Cholecalciferol (1) · Clinical Laboratory Information Systems (1) · Cyclosporine (1) · EDP-305 (1) · Emtricitabine (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)
Gilead Sciences (7) · Intercept Pharmaceuticals (5) · West China Hospital (5) · Cascade Pharmaceuticals, Inc (4) · Ipsen (4) · Zydus Therapeutics Inc. (4) · Xijing Hospital of Digestive Diseases (3) · Assistance Publique - Hôpitaux de Paris (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Kowa Research Institute, Inc. (2) · RenJi Hospital (2) · University of Alberta (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Arena Pharmaceuticals (1) · Beijing 302 Hospital (1)
United States (30) · China (22) · Canada (15) · Germany (14) · Italy (14) · Spain (14) · United Kingdom (14) · France (12) · Belgium (11) · Australia (9) · Austria (9) · Argentina (8) · Netherlands (8) · South Korea (8) · Greece (7)
Li Yang, MD (3) · Francesca Romana Ponziani (2) · Lynda Szczech, MD (2) · Adrian DiBisceglie, MD (1) · Andre Belous, MD, PhD (1) · Andrew Mason, MD (1) · Arena CT.gov Administrator (1) · Christian Trautwein, Prof.Dr. (1) · Christopher Bowlus, MD (1) · Deng Rong (1) · Deven Parmar (1)
PMID 40439725, PMID 10102814, PMID 21810549, PMID 24561556, PMID 24835895, PMID 25329189, PMID 28535810, PMID 29859173, PMID 30193962, PMID 32274345, PMID 33031833, PMID 33707216, PMID 34461299, PMID 35119627, PMID 35933430, PMID 36076306, PMID 36267872, PMID 36809835, PMID 38381664, PMID 38419761, PMID 39079613, PMID 39630028, PMID 39640219, PMID 39982546, PMID 40050288, PMID 40243391, PMID 40341605, PMID 40721581, PMID 41933275, PMID 42623335, PMID 42798953
2015 (1), 2016 (1)